CA2221826A1 - Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques - Google Patents

Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques Download PDF

Info

Publication number
CA2221826A1
CA2221826A1 CA002221826A CA2221826A CA2221826A1 CA 2221826 A1 CA2221826 A1 CA 2221826A1 CA 002221826 A CA002221826 A CA 002221826A CA 2221826 A CA2221826 A CA 2221826A CA 2221826 A1 CA2221826 A1 CA 2221826A1
Authority
CA
Canada
Prior art keywords
peptide
thr
htlv
composition
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002221826A
Other languages
English (en)
Inventor
Douglas K. Macfadden
Peter Louis Carlen
Penelope Reed-Doob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reed MacFadden Ltd
Original Assignee
Reed MacFadden Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reed MacFadden Ltd filed Critical Reed MacFadden Ltd
Priority to CA002221826A priority Critical patent/CA2221826A1/fr
Publication of CA2221826A1 publication Critical patent/CA2221826A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002221826A 1998-01-28 1998-01-28 Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques Abandoned CA2221826A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002221826A CA2221826A1 (fr) 1998-01-28 1998-01-28 Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002221826A CA2221826A1 (fr) 1998-01-28 1998-01-28 Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques

Publications (1)

Publication Number Publication Date
CA2221826A1 true CA2221826A1 (fr) 1999-07-28

Family

ID=29275253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002221826A Abandoned CA2221826A1 (fr) 1998-01-28 1998-01-28 Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques

Country Status (1)

Country Link
CA (1) CA2221826A1 (fr)

Similar Documents

Publication Publication Date Title
EP0898967B1 (fr) Utilisation des cellules myogeniques transduites pour l'analgésie et pour le traitement des anomalies de comportement et de perception
Glowa et al. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
CA2527039C (fr) Compositions d'analogues grf et leur utilisation
JPH10509428A (ja) 活性依存性神経栄養因子の神経栄養ペプチド
US20120213790A1 (en) Methods of treatment using il-16 antagonist peptides
CA2187336A1 (fr) Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
US5063206A (en) Compositions having use as treatment of neuropsychiatric deficits
AU663875B2 (en) Compositons for the treatment of chronic fatigue syndrome
JP2001515048A (ja) 百日咳毒素ｂオリゴマーによる抗ウイルス療法
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5686417A (en) Peptide T and related peptides in the treatment of HTLV-1 myelopathy and multiple sclerosis
IL105822A (en) Pharmacy products for use in the treatment of tropical spasticity
EP0960886B1 (fr) Peptide T et peptides associes destines au traitement des inflammations, notamment la sclerose en plaques
EP0415999B1 (fr) Preparations utilises comme traitement du psoriasis et des deficits neuropsychiatriques
US5534495A (en) Treatment of non-HIV neuropathic pain syndromes
Kotani et al. Identification of thyroiditogenic epitope on porcine thyroid peroxidase for C57BL/6 mice.
CA2221826A1 (fr) Peptide t et peptides apparentes utilises dans le traitement de la myelopathie attribuable au htlv-1 et de la sclerose en plaques
US8034777B2 (en) Modified anticholinergic neurotoxins as modulators of the autoimmune reaction
JPWO2002072134A1 (ja) 変形性関節症治療剤及び慢性関節リウマチ治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued